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Bone graft  ing is an essential procedure in musculoskeletal 
tumor surgery. After curettage or aspiration of various 
bone tumors, a large contained defect is usually generated. 
Autogenous bone has been considered the gold standard 
for graft  ing to this defect because it shows optimum skel-
etal incorporation. Nevertheless, complications to the 
donor site and its limited supply has led to the pursuit of 
alternative graft  ing materials such as allograft  s that include 
demineralized bone matrix (DBM) and various synthetic 
bone graft  s.
1,2)
Since Dreesman
3) first reported the use of calcium 
sulfate to obliterate the bone cavities caused by tuberculo-
sis, it has been used in the form of plaster of Paris (CaSO4) 
for the treatment of bone defects for more than a century. 
From 1996, medical grade calcium sulfate, which has min-
imal trace elements and it provides a uniform α crystalline 
structure with a predictable in vivo resorption rate, has 
Background: Injectable calcium sulfate is a clinically proven osteoconductive biomaterial, and it is an injectable, resorbable and 
semi-structural bone graft material. The purpose of this study was to validate the clinical outcomes of injectable calcium sulfate 
(ICS) grafts as compared with those of a demineralized bone matrix (DBM)-based graft for ﬁ  lling in contained bony defects created 
by tumor surgery.
Methods: Fifty-six patients (41 males and 15 females) with various bone tumors and who were surgically treated between Sep-
tember 2003 and October 2007 were included for this study. The patients were randomly allocated into two groups, and either an 
ICS graft (28 patients) or a DBM-based graft (28 patients) was implanted into each contained defect that was developed by the 
surgery. The radiographic outcomes were compared between the two groups and various clinical factors were included for the 
statistical analysis.
Results: When one case with early postoperative pathologic fracture in the DBM group was excluded, the overall success rates 
of the ICS and DBM grafting were 85.7% (24/28) and 88.9% (24/27) (p > 0.05), respectively. The average time to complete heal-
ing was 17.3 weeks in the ICS group and 14.9 weeks in the DBM group (p > 0.05). Additionally, the ICS was completely resorbed 
within 3 months, except for one case. 
Conclusions: Although the rate of resorption of ICS is a concern, the injectable calcium sulfate appears to be a comparable bone 
graft substitute for a DBM-based graft, with a lower cost, for the treatment of the bone defects created during surgery for various 
bone tumors. 
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Kim et al. Injectable Calcium Sulfate in Bone Tumor Surgery
Clinics in Orthopedic Surgery • Vol. 3, No. 3, 2011 • www.ecios.org
been available.
1) Calcium sulfate cement has been demon-
strated to be an osteoconductive and biocompatible mate-
rial without any adverse biologic reactions that occur aft  er 
the implantation.
4,5) Recently, an injectable and moldable 
form of calcium sulfate has been developed, and it off  ers 
many advantages when used to completely fill contained 
defects that have complex geometric shapes. Its resorption 
can be monitored radiographically because it is radiopaque. 
It hardens in situ and provides initial mechanical strength 
comparable to that of polymethyl-methacrylate (PMMA), 
which makes early weight-bearing possible even when it 
is graft  ed in the lower extremities.
6,7) It also can be drilled 
through and then receive adjunctive hardware. However, 
to the best of our knowledge, no clinical or radiographic 
comparative study on injectable calcium sulfate (ICS) has 
been reported, especially in the area of musculoskeletal 
tumor surgery. 
Th   e purpose of the current study was to assess the 
effi   cacy of ICS compared to that of a DBM-based graft   as a 
bone graft   substitute for the treatment of musculoskeletal 
tumors. We hypothesized that ICS would be an effective 
substitute comparable to a DBM-based graft for treating 
surgically created bone defects.
   
METHODS
Study Design
Between September 2003 and October 2007, 62 consecu-
tive patients underwent prospectively designed surgical 
treatment by the same surgeon (JHO). Th   ose patients with 
symptoms and either active benign or low grade malig-
nant bone tumor diagnosed on plain radiograph and mag-
netic resonance imaging (MRI) and that required a bone-
graft  ing procedure to fi  ll a contained defect aft  er curettage 
or aspiration of bone tumors were included in this study. 
Th   ose patients with uncontrolled diabetes, alcoholism, pe-
ripheral vascular disease, systemic infl  ammatory disease, 
use of systemic steroids, pathologic fracture through the 
tumor and high grade malignant bone tumor were exclud-
ed.  
Th   e type of graft  ing was decided by permuted block 
randomization at the time of surgery. Patients were ran-
domly allocated into two groups, and either an ICS-based 
graft (32 patients) or DBM-based graft (30 patients) was 
placed in each contained defect that was developed by the 
surgery. During the follow-up aft  er the surgery, 6 patients 
(10% of the enrolled patients) were excluded from this 
study. Two patients were diagnosed with high grade ma-
lignant bone tumor by the fi  nal histological examination; 
wide resection was performed immediately aft  er the fi  nal 
diagnosis. The remaining 4 patients were lost during the 
follow-up. Finally, the ICS group consisted of 28 patients 
and the DBM-based grafting group consisted of 28 pa-
tients in this study (90% of the initially enrolled patients). 
Th   is study was carried out with the approval of the insti-
tutional review board of the authors’ hospital, and written 
informed consent was requested and obtained from all the 
patients. 
   
Operative Procedure
Bone tumor, except for a simple bone cyst (SBC), was 
exposed via an appropriate sized cortical window accord-
ing to the size of the tumor. Th   en the intraosseous tumor 
was removed by using large and small curettes until no 
tumorous tissue was seen grossly. Next, the entire bony 
margin within the cavity was further removed with a high-
speed burr under direct vision and fluoroscopy. All the 
overhanging bony ledges were removed to ascertain the 
presence of any hidden tumor. The curetted tissue was 
sent to the Department of Pathology for frozen sectioning 
and the permanent pathologic diagnosis. When aggressive 
benign bone tumor and low grade malignant bone tumor 
were suspected according to the previous radiographic 
study or the frozen sections, adjuvant treatment with 99% 
anhydrous alcohol was applied for 10 minutes.
8) Aft  er suc-
tioning, extensive saline irrigation was performed to rinse 
out the alcohol. The volume of the contained defect was 
measured by the amount of irrigation solution that was 
used to fi  ll each defect. 
In the ICS group, minimally-invasive injectable 
graft (MIIG 1.1.5, Wright Medical Technology Inc., Ar-
lington, TN, USA) was mixed for 30 seconds to a smooth 
consistency using the manufacture’s vacuum mixer. The 
bone defect was filled within another one minute by us-
ing an injection syringe that contained ICS. We avoided 
overfi  lling or pressurizing the defect site. Subsequently, we 
allowed fi  ve minutes to set the ICS. More recently, a newer 
product of MIIG was developed (MIIG X3, Wright Medi-
cal Technology Inc.). Thus, we started using the newer 
version of MIIG from January 2007. It has 160% higher 
compressive strength than the previous product.
9) It also 
provides a longer working time; 2.5 minutes were allowed 
to inject this material into the bony defect and 11 minutes 
to set the ICS. In one case of an intertrochanteric lesion of 
the proximal femur, prophylactic fixation with compres-
sion hip screw was performed aft  er the setting of the ICS 
(Table 1, No. 19).
In the DBM group, a manufactured DBM (Ortho-
blast II, Integra OrthoBiologics Inc., Irvine, CA, USA) 
syringe was applied to the bone defect area and injection   193
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Table 1. Demographic Data of the Patients
No. Age
(yr) Gender Location Diagnosis Type of 
graft
Volume of 
the graft 
(mL)
Prophylactic 
ﬁ  xation
Time to 
resorption 
(wk)
Time to 
healing 
(wk)
Healing Complications
1 11 M Calcaneus SBC ICS (115)   8 No   2 Not healed No No
2 12 M Humerus SBC ICS (115) 30 No 15 35 Yes No
3 34 M Femur SBC ICS (115) 27 Yes 14 22 Yes No
4 20 M Calcaneus M-CS ICS (115) 12 No   6 Not healed No No
5 14 M Fibula OF ICS (115)   6 No   6 12 Yes No
6 35 M Ilium ABC ICS (115) 18 No 12 23 Yes No
7 11 F Calcaneus SBC  ICS (115)   7 No   5 13 Yes No
8 14 M Calcaneus SBC  ICS (115)   8 No 11 11 Yes No
9 43 F Tibia FD ICS (115) 18 No 11 13 Yes No
10 12 F Femur CB ICS (115) 27 No 14 25 Yes No
11 25 M Acetabulum SBC ICS (115)   7 No   5 14 Yes No
12 13 M Humerus SBC ICS (115) 26 No 15 24 Yes No
13 47 F Fibula IO-lipoma ICS (115)   3 No   6 13 Yes No
14 36 F Humerus L-CS   ICS (115) 25 No 12 Not healed No Fracture (3 mo)
15 34 M Fibula Chondroma ICS (115)   4 No   6 13 Yes No
16 43 M Humerus FD ICS (115) 19 No 11 11 Yes No
17 18 M Humerus SBC ICS (115) 24 No 11 38 Yes No
18 17 M Fibula L-OSA ICS (115)   4 No   6 11 Yes No
19 21 M Femur FD ICS (115) 23 Yes Not resorbed Not healed No Fracture (10 mo)
20 35 M Phalanx EC ICS (X3)   1 No   6   6 Yes No
21 53 F Humerus L-CS ICS  (X3) 18 No 15 22 Yes No
22 38 M Calcaneus IO-lipoma ICS (X3)   6 No 12 12 Yes No
23 19 M Tibia CB ICS (X3)   5 No   3 12 Yes No
24 55 F Humerus L-CS ICS  (X3)  21 No 12 24 Yes No
25 51 F Glenoid IO-ganglion ICS (X3)   1 No   3 12 Yes No
26 44 M Phalanx EC ICS (X3)   1 No   2 11 Yes No
27 25 M Patella ABC ICS (X3)   8 No   7 12 Yes No
28 33 M Phalanx EC ICS (X3)   1 No   6 12 Yes No
29 39 M Talus IO-ganglion DBM  3   No 12 Yes No
30 44 M Calcaneus IO-lipoma DBM  5 No 14 Yes No
31 28 M Patella ABC DBM + Allo 19 No 16 Yes Infection (I&D)
32 64 F Phalanx EC DBM   1 No   6 Yes No
33 53 M Talus IO-ganglion  DBM   2 No 13 Yes No
34 64 F Phalanx EC DBM   1 No   6 Yes No194
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was performed. When the volume of the contained defect 
was measured to be more than 5 mL, the cancellous al-
lograft   or autograft   was mixed with DBM and graft  ed due 
to the additional osteoconductive property. Concerning 
pathologic fracture during the early postoperative peri-
ods,
10) physical activity was restricted in the DBM group 
for 4 weeks in cases with an upper extremity lesion and for 
6 weeks in those patients with a lower extremity lesion. In 
one case of intertrochanteric lesion of the proximal femur, 
prophylactic fixation with compression hip screw was 
performed aft  er the curettage of the intraosseous lipoma 
(Table 1, No.  52).
   
Operative Procedure for SBC
For patients with SBC, the procedures were guided by 
fluoroscopy. Two 10-gauge Peverty needles (Kyungwon 
Medical, Seoul, Korea) were inserted proximally and dis-
tally into each cavity. If a cyst was multi-locular, then the 
procedures were performed separately in each cavity. Th  e 
diagnosis of a SBC was confi  rmed by the aspiration of the 
straw-colored fl  uid. Th   e contents of the cyst were further 
aspirated, and then cystography proceeded to confi  rm the 
Table 1. Continued
No. Age
(yr) Gender Location Diagnosis Type of 
graft
Volume of 
the graft 
(mL)
Prophylactic 
ﬁ  xation
Time to 
resorption 
(wk)
Time to 
healing 
(wk)
Healing Complications
35 48 F Tibia ABC DBM + Auto 10 No 36 Yes No
36 52 F Phalanx IO-ganglion DBM   2 No   7 Yes No
37 40 M Phalanx EC DBM   1 No   5 Yes No
38 25 M Radius FD DBM   3 No 16 Yes No
39 42 F Phalanx EC DBM   1 No   6 Yes No
40 64 F Calcaneus IO-lipoma DBM   5 No 14 Yes No
41   5 M Femur SBC DBM + BM 13 No Not healed No No
42 11 M Humerus SBC DBM + BM 24 No 18 Yes No
43 20 M Ilium SBC DBM + BM 21 No 40 Yes No
44 64 M Tibia FD DBM + Allo 25 No 12 Yes No
45   9 M Fibula NOF DBM   2 No 16 Yes No
46 15 M Cuneiform GCT  DBM   3 No 14 Yes No
47 11 M Humerus SBC DBM + BM 18 No Not healed No No
48   2 M Femur OO DBM   1 No 14 Yes No
49 25 M Humerus SBC DBM + BM 23 No Not healed No No
50   7 F Femur NOF  DBM   5 No 28 Yes No
51   7 M Femur SBC DBM + BM 23 No 20 Yes No
52 38 M Femur IO-lipoma DBM + Allo 35 Yes 12 Yes No
53 12 M Calcaneus SBC DBM + BM 17 No 12 Yes No
54 41 M Metacarpus EC DBM   2 No 12 Yes No
55 26 M Femur LCH DBM + Auto   8 No Not identiﬁ  ed No Fracture (11D)
56 14 M Humerus SBC DBM + BM 27 No   8 Yes No
SBC: simple bone cyst, M-CS: myxoid chondrosarcoma, OF: ossifying fibroma, ABC: aneurismal bone cyst, FD: fibrous dysplasia, CB: chondroblastoma, IO-
lipoma: intraosseous lipoma, L-CS: low grade chondrosarcoma, L-OSA: low grade osteosarcoma, IO-ganglion: intraosseous ganglion, EC: enchondroma, NOF: 
nonossifying ﬁ  broma, GCT: giant cell tumor, OO: osteoid osteoma, LCH: Langerhans cell histiocytosis, 115: minimally-invasive injectable graft (MIIG) 1.1.5, X3: 
MIIGX3, Allo: allogenic bone graft, Auto: autologous bone graft, ICS: injectable calcium sulfate, DBM: demineralized bone matrix, BM: bone marrow.195
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full visualization of each cyst. Th   e cyst was irrigated with 
normal saline to wash off the contrast medium, and ei-
ther ICS or DBM was injected within another one minute 
into the defect. As for the ICS group, the same procedures 
were applied as those for an injection aft  er the curettage. 
In one patient whose cyst was located near the lesser tro-
chanter, prophylactic fi  xation with reconstruction nail was 
performed aft  er injection of the ICS. In the DBM group, 
autogenous bone marrow was aspirated from the anterior 
iliac crest using an 11-gauge needle (Angiotech, Wheeling, 
IL, USA). Multiple sites were punctured to obtain 9 to 18 
mL of bone marrow through a single skin-puncture site, 
with taking no more than 2 to 3 mL from each site.
11) Th  e 
DBM was then mixed with aspirated bone marrow and it 
was injected through the Peverty needles. Th   e volume of 
the cyst was measured by the preoperative radiography 
and using the formula (π/6 × length × width × height).
12) 
Physical activity was restricted in the DBM group for 4 
weeks for the cases with a humeral lesion and for 6 weeks 
in those with a lower extremity lesion. 
   
Radiographic Assessment
Postoperative follow-up was scheduled at 2, 6, and 12 
weeks and then every 3 months after the surgery until 
bony union happened. The assessment was based on the 
radiographic fi  ndings and the presence of complications. 
Th   e degree of calcium sulfate resorption was determined 
by the anteroposterior (AP) and lateral views at each fol-
low-up. Th   e time to complete resorption was recorded. We 
defi  ned the time to healing as the period that was required 
to achieve bony trabeculation visualized in the osseous de-
fect on the AP and lateral views.
   
Statistical Analysis
Th   e results of the ICS graft   were compared with those of 
the DBM-based graft   in terms of the overall success rate 
and the time to healing. Additional factors such as age, 
gender, the location of the tumor, additional fi  xation and 
the volume of the defect were also evaluated to determine 
the effi   cacy of the treatment. Student’s t-test was used for 
the continuous variables and chi-squared test was used to 
evaluate categorical variables. Fisher’s exact test was used 
to compare the two groups with a smaller sample size (n 
< 5). Linear regression analysis was used to determine the 
correlation between the volume of the defect and the time 
to graft resorption or the time to bone healing. We per-
formed all the statistical analyses with SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA).
RESULTS
Clinical Findings
The patients’ medical records were reviewed for the de-
mographic and perioperative data (Table 1). The overall 
patient population consisted of 41 males and 15 females. 
Th   eir mean age was 30.4 years (range, 2 to 64 years) and 
the mean follow-up time was 17.3 months (range, 3 to 46 
months). Each group was compared in terms of the patient 
demographics, the location of the tumor, additional fi  xa-
tion and the volume of the defect, but no statistical diff  er-
ence was observed between the two groups (Table 2).
   
Th   e Success Rate 
One case of pathologic fracture was excluded in calculat-
ing the overall success rate, which occurred on the 11th 
postoperative day in the DBM group (Table 1, No. 55). 
Table 2. Details of the ICS-based Grafting Group and the DBM-
based Grafting Group
ICS group
(n = 28)
DBM group
(n = 28) p-value
Mean age (yr) 29.0 (11-55) 31.1 (2-64) 0.666
Gender (% of male) M : F = 20 : 8 (71.4%) M : F = 21 : 7 (75%) 0.763
Internal ﬁ  xation   2 (7.1) 1 (3.6) 0.553
Volume of the defects
 (mean, mL) 12.8 10.7 0.442
Location of tumor
  Humerus 7 (25)   4 (14.3) 0.503
  Calcaneus    5 (17.9)   3 (10.7) 0.705
  Femur    3 (10.7)   6 (21.4) 0.469
  Phalanx    3 (10.7)   5 (17.9) 0.705
  Fibula    4 (14.3) 1 (3.6) 0.352
Values are presented as number (%) unless otherwise stated.
ICS: injectable calcium sulfate, DBM: demineralized bone matrix.
Table 3. Comparison of the Success Rate 
ICS group (%) DBM group (%) p-value
SBC      7/8 (87.5)     5/8 (62.5) 0.569 
On-SBC 17/20 (85.0)   19/19 (100.0) 0.231 
Overall 24/28 (85.7) 24/27 (88.9) 1.000 
ICS: injectable calcium sulfate, DBM: demineralized bone matrix, SBC: simple 
bone cyst.196
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As a result, the overall success rates of the ICS and DBM 
groups were 85.7% (24/28) and 88.9% (24/27), respective-
ly. Th   e success rates of the ICS and DBM groups of SBC 
patients were 87.5% (7/8) and 62.5% (5/8), respectively. As 
for the bone tumors other than SBC, the success rates of 
the ICS and DBM were 85.0% (17/20) and 100% (19/19) 
in each group. Th   ere was no statistical diff  erence between 
the two groups in each disease category (Table 3). 
To verify whether any factor had an infl  uence on the 
success rates of the procedures, we compared the patients 
Fig. 1. The serial radiographs of a 55-year-old female patient show (A) intramedullary calcified bone tumor in the proximal humeral metaphysis 
preoperatively. The follow-up radiographs taken (B) immediately after the operation, (C) 6 weeks postoperatevely and, (D) 12 weeks postoperatively 
show the gradual resorption of the injectable calcium sulfate. (E) The ﬁ  nal radiograph shows skeletal incorporation.
Fig. 2. Linear regression analysis demonstrated that the volume of the 
injectable calcium sulfate (ICS) graft was correlated with (A) the time to 
resorption and (B) the time to healing. On the contrary, (C) the volume 
of the demineralized bone matrix (DBM)-based graft was not correlated 
with the time to healing.197
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in the ICS group with those in the DBM group in terms of 
age, gender, the location of the tumor, additional fi  xation 
and the volume of the defect. However, none of these fac-
tors were found to statistically affect the success rates of 
the bone healing in either group. 
   
Time to Resorption/Healing 
Th   e mean time to healing was 17.3 weeks (range, 6 to 38 
weeks) in the ICS group and 14.9 weeks (range, 5 to 40 
weeks) in the DBM group (p > 0.05). Additionally, the ICS 
graft   was completely resorbed within 3 months except for 
one case with pathologic fracture. All of the defects healed 
in a centripetal fashion; the more peripherally placed cal-
cium sulfate was resorbed fi  rst and the more central por-
tion was the last to disappear (Fig. 1). Th   e average time to 
resorb was 8.9 weeks (range, 2 to 17 weeks). The rate of 
resorption and healing of ICS depended on the volume of 
the defect, but the rate of healing in the DBM group did 
not show linearity (Fig. 2).  
   
Complications
There were two cases of pathologic fracture in the ICS 
group. The first patient had been treated for low grade 
chondrosarcoma on the diaphysis of the humerus (Table 
1, No. 14). We performed curettage and ICS grafting as 
described earlier without prophylactic fi  xation. She com-
plained of a pain aft  er slipping down at 12 weeks postoper-
atively; the plain radiograph showed an undisplaced frac-
ture through the graft  ing region with complete absorption 
of the ICS. We treated her conservatively with an arm-
sling, and bony union was achieved 2 months later. We 
regarded this case as a failed healing because the fracture 
occurred after the resorption of the ICS. The second pa-
tient had fi  brous dysplasia on his left   proximal femur and 
mainly on the intertrochanteric region (Table 1, No. 19). 
We performed curettage through the bony window on the 
lateral cortex of the proximal femur and ICS was graft  ed. 
Aft  er the setting period of the ICS, we reamed through the 
calcium sulfate for internal fixation to the femoral head. 
However, it was very diffi   cult to ream and make a hole for 
the lagging screw; it took as much as 30 minutes to com-
plete this procedure. Fortunately, we succeeded to fi  x the 
lagging screw internally through the canal. Aft  er the op-
eration, he complained of a sustained pain on his left   hip; 
we continued to recommend to him to walk with a crutch. 
Th   e follow-up plain radiograph showed a cortical breakage 
on the superior femur neck at 6 months postoperatively, 
and pathologic fracture with an incomplete resorption of 
ICS was evident 10 months postoperatively. We performed 
curettage of the remnant calcium sulfate and a salvage pro-
cedure with internal fi  xation and autogenous bone graft  ing 
(Fig. 3). No evidence of tumor recurrence was identifi  ed.
Th   ere were two patients whose lesions failed to heal. Th  e 
lesions were located in the calcaneus; one was myxoid 
chondrosarcoma and the other was SBC (Table 1, No. 4, 8). 
Th   e patient with chondrosarcoma, who we previously re-
ported on as a case report,
13) had a sustained pain aft  er the 
operation. Plain radiograph showed complete resorption 
of the ICS, and MRI revealed cystic change in the graft  ing 
area (Fig. 4). In the other patient with SBC, persistence of 
a cyst was evident on the plain radiograph. In each patient, 
the time period to complete resorption of ICS was mea-
Fig. 3. The anteroposterior radiographs of a 21-year-old man with ﬁ  brous dysplasia of his left femur neck show (A) the three months postoperative 
view after the curettage and injectable calcium sulfate grafting with prophylactic ﬁ  xation. (B) Six months postoperatively, he complained of continuous 
pain on his left hip, and the radiograph showed the cortical breakage on the superior aspect of the femur neck (arrow). (C) Ten months postoperatively, 
complete fracture occurred in spite of activity restriction. Note that the calcium sulfate is not completely resorbed. (D) The final radiograph after 
curettage of the remnant calcium sulfate and internal ﬁ  xation with autogenous bone grafting. 198
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sured to be 6 weeks and 2 weeks, respectively.
Th   ere were three patients whose lesion failed to heal 
after the DBM-based grafting. All of the three patients 
were diagnosed as having SBC, two on the humerus and 
one on the femur. One patient in the DBM group with a 
wound infection was treated successfully with debride-
ment and administration of intravenous antibiotics (Table 
1, No. 3).
DISCUSSION
The advantages of an autograft are well established even 
though there is a dearth of research with level I evidence. 
An autograft   has been considered the gold standard for the 
management of osseous defects because it is usually well 
incorporated into the surrounding bone with both osteo-
conductive and osteoinductive biologic capacity.
14) Despite 
its effectiveness, several limitations do exist when using 
autograft  s; its acquisition requires an additional incision, 
the operative time, intraoperative bleeding and postopera-
tive morbidity especially prolonged pain are increased. In 
addition, postoperative infection, pathologic fracture at 
the donor site, formation of neuroma, growth impairment 
in infants and children, the limited quantities and the vari-
able quality of the harvested autograft   are also the negative 
factors.
2,15) Th   is is why surgeons have sought a material that 
could be eff  ectively used instead of autogenous bone.
In the present study, we examined the performance 
of ICS as a bone-graft   substitute to fi  ll the contained bone 
defects. Th   e radiographic results showed the comparable 
success rate with the DBM-based graft  . Th   e mean time to 
healing in the ICS group was 17.3 weeks, which tended to 
be more delayed than the DBM group, but this was with-
out statistical difference. Resorption of ICS was predict-
able in a timely fashion and this depended on the volume 
of the defect. All but one of the ICS graft  s were completely 
resorbed within 3 months. The patients did not experi-
ence any pathologic fracture during the early postopera-
tive period, which was attributed to the initial mechanical 
strength that was comparable to PMMA.
16) The current 
results agree with the results reported by Kelly et al.
17) In 
their multicentered study, the radiographic results showed 
that 99% of the calcium sulfate had been resorbed and 
88% of the defect was filled with trabeculated bone at 6 
months postoperatively. Clayer
18) reported that calcium 
sulfate cement was resorbed completely within 8 weeks 
in his case series with aneurismal bone cysts, and Clayer 
found favorable early clinical and radiological responses 
with a low complication rate. Gitelis et al.
19) also reported 
that the calcium sulfate was a reasonable alternative to an 
autogenous bone graft   for treating benign bone lesions. 
Calcium sulfate acts as an osteoconductive matrix 
that provides a scaff  old for a new bone to grow.
4) It allows 
for in-growth of blood vessels and osteogenic cells. In ad-
dition, it resorbs as a newly formed bone remodels and 
it restores the original anatomic features and structural 
properties.
20) Peltier and Jones
21) asserted that osteoconduc-
tion requires the bone-graft   substitute to have a resorption 
rate similar to the rate of new-bone formation. Owing to 
the recent advances in producing calcium sulfate as a bone 
graft   substitute, such as the process that allows minimiz-
ing the trace elements and making them into an extremely 
uniform crystalline pattern, the rate of its resorption is 
consistent with that of the new bone growth.
22) However, 
some authors have criticized calcium sulfate for its rapid 
resorption, which happens before the bone tissue has had 
time to grow into the defect.
17,19,23) Likewise, the speed of 
resorption was too fast to form new bone ingrowth in two 
calcaneal lesions in the current study at six and two weeks, 
respectively, which seemed to be the cause of the cyst for-
Fig. 4. The radiographs showed a 20-year-old man who had undergone surgery for myxoid chondrosarcoma that arose from the calcaneus (A, B). (A) 
The immediate postoperative view shows the status of injectable calcium sulfate injection. At the follow-up, the calcium sulfate was (B) gradually 
resorbed in a centripetal fashion, and (C) it was completely resorbed at 6 weeks postoperatively. (D) The magnetic resonance imaging taken 6 months 
postoperatively shows a peripherally enhanced cystic lesion within the calcaneus, and this indicated failure of healing.199
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mation. As another reason, we attributed this failure to the 
poor blood supply to this region. From this point of view, 
confl  icting results have been presented regarding the suc-
cessful use of calcium sulfate graft  . Walsh et al.
5) reported 
that the complete healing of the defect was not observed 
with calcium sulfate alone, and they hypothesized that the 
calcium sulfate acts as a barrier to additional bone infil-
tration. In contrast, by spectral analysis, Yi et al.
7) found 
evidence that the calcium sulfate cement resorption was 
paralleled with bone ingrowth. Bucholz
1) reported positive 
results when calcium sulfate was used as an osteoconduc-
tive bone void filler for the expansion of grafts and for 
the filling of bone graft harvest sites. They also reported 
that there was no generation of undesirable dissolution 
products during this process. Likewise, the resorption 
rate of the ICS seems to be paralleled with the rate of 
bone ingrowth in most of the cases of the current study. 
However, we recommend more careful use of the ICS for 
optimal bone healing, and especially in large or distal le-
sion of the extremities where the blood supply is poor. In 
addition, hardened calcium sulfate can be drilled through, 
but it cannot be easily reamed through. Excessive reaming 
through ICS may cause thermal injury to the surrounding 
tissues, which may harm the process of bone ingrowth. 
Th   e present study also demonstrated that complete resorp-
tion of calcium sulfate may not indicate complete bone 
healing, and the mechanical strength of the grafted area 
could be weaker than the initial strength after complete 
resorption of calcium sulfate has been identifi  ed. 
We also investigated the effectiveness of DBM as 
another alternative to an autograft in the present study. 
DBM was prepared from a freeze-dried allograft with a 
method that may preserve some of the osteoinductive 
and osteoconductive properties.
24) When it is mixed into 
a glycerin carrier, this gives the material a gel-like consis-
tency that can be injected through large gauge needles. 
Previous studies have identifi  ed that DBM graft  ing dem-
onstrated healing that was comparable
25) or superior
26) to 
the results achieved by the standard iliac bone graft  . In the 
current study, complete healing of contained defects oc-
curred in 24 of 27 patients (88.9%). In the SBC patients, 
DBM and autogenous bone marrow were combined to 
form one composite graft to enhance the osteoinductive 
properties. Th   e success rate with one injection was 62.5% 
(5/8) which was comparable to a previous study.
27) As for 
the five patients who had a defect larger than 5 mL, the 
composite graft   with a morsilized autograft   or an allograft   
was performed to impart additional osteoinductive and 
osteoconductive properties to the composite graft, and 
the results were satisfactory with a success rate of 100% 
when excluding the case with early postoperative fracture. 
Despite these good results, DBM has some limitations for 
its use; it is expensive and it may carry the risk of disease 
transmission as it is a human product. Most DBM prepa-
rations lack substantial mechanical properties, and there 
is no signifi  cant improvement in mechanical strength dur-
ing the early stages of healing.
10,28) Also, the osteoinductive 
potential can vary depending on the donor
29) and can be 
infl  uenced by the tissue processing.
30)
The present study has several limitations. First, we 
did not have a control group with standard autogenous 
iliac bone graft  s, although there has been no prospective 
randomized controlled study for autogenous grafts to 
validate their eff  ectiveness. Instead, we had tried to make 
the DBM group have optimal healing capacity with ad-
ditional auto- or allograft and bone marrow. Second, we 
did not perform histological or mechanical studies for the 
healed tissues aft  er the ICS graft  ing. Histomorphometric 
analysis or mechanical testing for assessing the compres-
sive strength during each healing period would make it 
possible to observe more comparative results. Third, we 
cannot suggest the cut-off   value to defi  ne a ‘large’ defect as 
associated with the healing capacity of ICS. A larger study 
population would be needed for this type of analysis. Last, 
the exact timing of bony incorporation was difficult to 
determine on plain radiographs. Th   e addition of CT scans 
would allow more accurate evaluation of the healing sta-
tus. 
In conclusion, injectable calcium sulfate appears to 
be an eff  ective bone graft   substitute that is comparable for 
a DBM-based graft  , with a lower cost, for the treatment of 
the bone defects created during surgery for various bone 
tumors. 
However, when the defect size is considerably large 
or when the blood supply to the lesion seems to be poor, 
ICS should be used with more caution. 
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